Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
about
Immunological Evaluation of Recent MUC1 Glycopeptide Cancer VaccinesRoles for major histocompatibility complex glycosylation in immune functionVirus-Based Nanoparticles as Versatile NanomachinesMolecular mimics of the tumour antigen MUC1Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo.Lipopeptide-Coated Iron Oxide Nanoparticles as Potential Glycoconjugate-Based Synthetic Anticancer Vaccines.MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.Antigen choice determines vaccine-induced generation of immunogenic versus tolerogenic dendritic cells that are marked by differential expression of pancreatic enzymes.Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune ResponsesEarly in vivo signaling profiles in MUC1-specific CD4(+) T cells responding to two different MUC1-targeting vaccines in two different microenvironmentsCD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-κB signal pathway.Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen.Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10.Dendritic cells and the maintenance of self-tolerance.Cancer vaccines inducing antibody production: more pros than cons.The sweet side of tumor immunotherapy.Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer.MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.Investigation of a new tumor-associated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer.
P2860
Q26740513-8B695A2E-4F0D-441A-8F98-4C10C575BF76Q27013984-0025F341-A617-4784-AD4C-0492969560C8Q28068538-8B5A48A1-51E7-4690-AC8F-1489302D7C32Q28485169-31CA731F-9AF6-4F35-AC26-A1EF951A4EABQ34427407-ADE47A72-6CC8-484C-A39D-5E0CD46CA197Q35705462-23C6181B-EE06-489F-ABB4-295A1AB8EEFDQ35898801-23D690CD-95F1-4EB5-B0A2-6869E3F7F1C8Q36508191-1C128B8D-1FE6-41AE-A344-F2B38CAE6ACFQ36718256-163AA884-1A24-4F09-9B14-BB9A18296085Q36758192-7742504A-9709-414B-B576-5FE60A2A21C3Q36815144-EF090EEF-90E0-4DFD-9AAB-28999BD81A35Q36866169-D67A7F9D-1C03-4CDE-9E93-A2E87709F15FQ37029731-35885110-11A1-42EE-A706-E0C16CB5FFFBQ37222171-9D36CD58-AFAC-4A52-98A2-712D7D9EBFB4Q37498983-D3E3D3DF-6D7E-4066-BC3E-B98E93CF6BC3Q37587225-E524DBE1-0BA7-48B8-BB97-BABF0F76848FQ37895963-05A11715-DD28-44F3-975A-CE40E0C81ACDQ37932519-5EF14F67-6306-42B2-AC78-FB6B81227FE6Q38031282-39EAB7D8-437A-4199-9B42-49D7C7E4DBA7Q38089936-6FEF3AE9-FE23-4D59-BB6E-57E2F71C0BD1Q38091088-079154C2-639A-45CD-8458-A7EB23EDD933Q39169405-5DCCDE69-5BE9-410D-B2C7-92357EF7A855Q41636538-F254B69F-1AE8-4469-B61E-31519747A24CQ41876001-5C8DE8B7-FF37-4873-A71E-B1A1754CB7FD
P2860
Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@ast
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@en
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@nl
type
label
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@ast
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@en
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@nl
prefLabel
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@ast
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@en
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@nl
P2093
P2860
P1433
P1476
Tumor antigen epitopes interpr ...... fect cancer vaccine responses.
@en
P2093
Jean Gariépy
Michael S Turner
Olivera J Finn
Sean O Ryan
P2860
P304
P356
10.1158/0008-5472.CAN-09-4519
P407
P577
2010-06-29T00:00:00Z